Pharmacokinetics of Antituberculosis Drugs in Pulmonary Tuberculosis Patients with Type 2 Diabetes

Altered pharmacokinetics of antituberculosis drugs may contribute to an increased risk of tuberculosis treatment failure for diabetic patients. We previously found that rifampin exposure was 2-fold lower in diabetic than in nondiabetic tuberculosis patients during the continuation phase of treatment...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ruslami, Rovina, Nijland, Hanneke M. J., Adhiarta, I. Gusti N., Kariadi, Sri H. K. S., Alisjahbana, Bachti, Aarnoutse, Rob E., van Crevel, Reinout
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology (ASM) 2010
Gaiak:
Pharmacology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2825975/
https://ncbi.nlm.nih.gov/pubmed/20038625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00447-09
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak